KRN 5500 presents phase II: weak efficacy? KRN 5500* has been tested in a phase II trial and the results were presented on april 20, 2010. More details will be presented in May in Athens, during the neuropathic pain congress. KRN 5500 is a spicamycin derivative and is available as a solution for intravenous (IV) … Meer lezen over KRN 5500 presents phase II: weak efficacy?
Kopieer en plak deze URL in de WordPress-site om in te sluiten
Kopieer en plak deze code in de site om in te sluiten.